Neurosterix

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Newleos Therapeutics

The company develops oral small-molecule drugs to treat neuropsychiatric disorders, including anxiety and substance use disorders, for patients seeking therapies with fewer side effects.

Monument Therapeutics

This biotech company develops digital biomarkers and targeted drugs to treat patients with schizophrenia and other neurological conditions.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.